FDA Largely Rejects Prometheus Petition On Drug Risks
The U.S. Food and Drug Administration has told Prometheus Laboratories Inc. that it won't quickly develop regulations clarifying how rival drugmakers should craft required risk-reduction measures and downplayed concerns that unanswered...To view the full article, register now.
Already a subscriber? Click here to view full article